The Time Has Come for Targeted Therapies for AML: Lights and Shadows

Acute myeloid leukemia (AML) is a complex disease characterized by genetic and clinical heterogeneity and high mortality. After 40 years during which the standard of care for patients evolved very little, the therapeutic landscape has recently seen rapid changes, with the approval of eight new drugs...

Descripción completa

Detalles Bibliográficos
Autores principales: Fiorentini, Alessandro, Capelli, Debora, Saraceni, Francesco, Menotti, Diego, Poloni, Antonella, Olivieri, Attilio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359996/
https://www.ncbi.nlm.nih.gov/pubmed/32700072
http://dx.doi.org/10.1007/s40487-019-00108-x
_version_ 1783559149319094272
author Fiorentini, Alessandro
Capelli, Debora
Saraceni, Francesco
Menotti, Diego
Poloni, Antonella
Olivieri, Attilio
author_facet Fiorentini, Alessandro
Capelli, Debora
Saraceni, Francesco
Menotti, Diego
Poloni, Antonella
Olivieri, Attilio
author_sort Fiorentini, Alessandro
collection PubMed
description Acute myeloid leukemia (AML) is a complex disease characterized by genetic and clinical heterogeneity and high mortality. After 40 years during which the standard of care for patients evolved very little, the therapeutic landscape has recently seen rapid changes, with the approval of eight new drugs by the Food and Drug Administration (FDA) within the last 2 years, providing new opportunities, as well as new challenges, for treating clinicians. These therapies include FLT3 inhibitors midostaurin and gilteritinib, CPX-351 (liposomal cytarabine and daunorubicin), gemtuzumab ozogamicin (GO, anti-CD33 monoclonal antibody conjugated with calicheamicin), IDH1/IDH2 inhibitors ivosidenib and enasidenib, Hedgehog inhibitor glasdegib, and BCL-2 inhibitor venetoclax. In this review, we summarize currently available data on these new drugs and discuss the rapidly evolving therapeutic armamentarium for AML, focusing on targeted therapies.
format Online
Article
Text
id pubmed-7359996
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-73599962020-07-20 The Time Has Come for Targeted Therapies for AML: Lights and Shadows Fiorentini, Alessandro Capelli, Debora Saraceni, Francesco Menotti, Diego Poloni, Antonella Olivieri, Attilio Oncol Ther Review Acute myeloid leukemia (AML) is a complex disease characterized by genetic and clinical heterogeneity and high mortality. After 40 years during which the standard of care for patients evolved very little, the therapeutic landscape has recently seen rapid changes, with the approval of eight new drugs by the Food and Drug Administration (FDA) within the last 2 years, providing new opportunities, as well as new challenges, for treating clinicians. These therapies include FLT3 inhibitors midostaurin and gilteritinib, CPX-351 (liposomal cytarabine and daunorubicin), gemtuzumab ozogamicin (GO, anti-CD33 monoclonal antibody conjugated with calicheamicin), IDH1/IDH2 inhibitors ivosidenib and enasidenib, Hedgehog inhibitor glasdegib, and BCL-2 inhibitor venetoclax. In this review, we summarize currently available data on these new drugs and discuss the rapidly evolving therapeutic armamentarium for AML, focusing on targeted therapies. Springer Healthcare 2020-01-24 /pmc/articles/PMC7359996/ /pubmed/32700072 http://dx.doi.org/10.1007/s40487-019-00108-x Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Review
Fiorentini, Alessandro
Capelli, Debora
Saraceni, Francesco
Menotti, Diego
Poloni, Antonella
Olivieri, Attilio
The Time Has Come for Targeted Therapies for AML: Lights and Shadows
title The Time Has Come for Targeted Therapies for AML: Lights and Shadows
title_full The Time Has Come for Targeted Therapies for AML: Lights and Shadows
title_fullStr The Time Has Come for Targeted Therapies for AML: Lights and Shadows
title_full_unstemmed The Time Has Come for Targeted Therapies for AML: Lights and Shadows
title_short The Time Has Come for Targeted Therapies for AML: Lights and Shadows
title_sort time has come for targeted therapies for aml: lights and shadows
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359996/
https://www.ncbi.nlm.nih.gov/pubmed/32700072
http://dx.doi.org/10.1007/s40487-019-00108-x
work_keys_str_mv AT fiorentinialessandro thetimehascomefortargetedtherapiesforamllightsandshadows
AT capellidebora thetimehascomefortargetedtherapiesforamllightsandshadows
AT saracenifrancesco thetimehascomefortargetedtherapiesforamllightsandshadows
AT menottidiego thetimehascomefortargetedtherapiesforamllightsandshadows
AT poloniantonella thetimehascomefortargetedtherapiesforamllightsandshadows
AT olivieriattilio thetimehascomefortargetedtherapiesforamllightsandshadows
AT fiorentinialessandro timehascomefortargetedtherapiesforamllightsandshadows
AT capellidebora timehascomefortargetedtherapiesforamllightsandshadows
AT saracenifrancesco timehascomefortargetedtherapiesforamllightsandshadows
AT menottidiego timehascomefortargetedtherapiesforamllightsandshadows
AT poloniantonella timehascomefortargetedtherapiesforamllightsandshadows
AT olivieriattilio timehascomefortargetedtherapiesforamllightsandshadows

Ejemplares similares